Key Highlights
- SUIC will obtain a 51% interest in Vision Renu in exchange for 30,000,000 common shares.
- The issued shares will represent about 35% of SUIC’s fully‑diluted share base.
- Over 5000 units are projected for the 2028 market rollout.
SUIC Worldwide Holdings Ltd. (OTC: SUIC) disclosed a definitive agreement to acquire a controlling portion of Taiwan‑based Vision Renu Corporation. The deal involves an exchange of 30,000,000 SUIC common shares for a majority stake, reshaping the firm’s strategic focus on high‑tech medical devices.
Controlling Stake Acquisition
Under the terms, SUIC will secure a 51% ownership interest in Vision Renu. The transaction is structured as a share exchange, aligning with tax‑free reorganization provisions under the Internal Revenue Code. This move positions SUIC to integrate Vision Renu’s research and manufacturing capabilities into its existing operations.
Diluted Equity Impact
The 30,000,000 shares allocated to Vision Renu’s chairman will compose roughly 35% of SUIC’s total outstanding shares on a fully‑diluted basis. This dilution reflects the company’s commitment to expanding its capital base while preserving shareholder value through strategic growth.
Leadership Realignment
Following the agreement, SUIC’s board underwent a reconstitution. Shan Hua Peng was appointed as director and chief financial officer, reinforcing the leadership team for post‑acquisition integration.
Medical‑Device Portfolio Expansion
Vision Renu specializes in research and production of advanced medical devices, targeting aging‑related health challenges. The acquisition adds two flagship products to SUIC’s lineup and opens access to government‑backed research programs, enhancing the firm’s competitive edge in the healthcare market.
Projected Order Volume
The combined entity anticipates securing over 5000 units for the 2028 fiscal period, reflecting strong demand across Asian markets. This forecast underscores the potential revenue uplift from newly integrated product offerings.
SEC Filing Timeline
The required regulatory filing will be completed within 70 days as mandated by the Securities and Exchange Commission. The filing will include audited financial statements for the preceding two years and pro forma interim reports, ensuring transparency for investors.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.


_11_19_2026_12_58_12_592184.jpg)



Please wait processing your request...